Goldman Sachs
BBNX

Goldman Sachs’s Beta Bionics BBNX Stock Holding History

Goldman Sachs’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Sell
121,334
-284,074
-70% -$4.2M ﹤0.01% 4952
2025
Q4 		$12.4M Buy
405,408
+6,155
+2% +$164K ﹤0.01% 2881
2025
Q3 		$7.93M Buy
399,253
+88,252
+28% +$1.55M ﹤0.01% 3198
2025
Q2 		$4.53M Buy
311,001
+252,579
+432% +$3.58M ﹤0.01% 3524
2025
Q1 		$715K Buy
+58,422
New +$1.09M ﹤0.01% 4942

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's BBNX Position: Q1 2026 in Review

Goldman Sachs reduced its Beta Bionics (BBNX) stake by 70% in Q1 2026, selling an estimated $4.2M and leaving 121,334 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4952.

Goldman Sachs first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.4M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Goldman Sachs held 121,334 shares of Beta Bionics worth $1.22M as of Q1 2026.
  • Goldman Sachs sold 284,074 Beta Bionics shares in Q1 2026, an estimated $4.2M.
  • Beta Bionics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4952 holding.
  • Goldman Sachs first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Goldman Sachs's Beta Bionics position peaked at $12.4M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.